All News

Tecentriq numerically increased the rates of chemotherapy-induced ovarian failure compared with chemotherapy alone for patients with triple-negative breast cancer.

Verzenio showed meaningful improvement for some patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 treatment.

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast cancer after initial therapy.

Dan, diagnosed with stage 4 pancreatic cancer, shares his journey to remission and insights on clinical trials and patient advocacy.

Nuvisertib plus momelotinib is safe and generated improvements in symptom burden, spleen volume, and anemia outcomes in relapsed/refractory myelofibrosis.

Giredestrant generated improved outcomes over standard endocrine therapy in patients with ER+/HER2–, medium- and high-risk early breast cancer.

Progression-free survival was not statistically significant with Trodelvy versus chemotherapy as first-line treatment in HR+/HER2– metastatic breast cancer.

Emmy-winning journalist and author, Suleika Jaouad, delivered the keynote address at the inaugural Blood Cancer Heroes event.

KLN-1010 was associated with deep, ongoing minimal residual disease (MRD)–negative responses in multiple myeloma.

Real-world treatment with Yescarta demonstrated durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Dexamethasone before Yescarta reduced the severity of ICANS but did not change how often ICANS or CRS occurred in patients with LBCL.

Pelabresib plus Jakafi delivered stronger, clinically meaningful benefits versus Jakafi alone for people with untreated myelofibrosis.

Tecvayli plus Darzalex Faspro improved overall and progression-free survival versus standard daratumumab regimens in relapsed/refractory multiple myeloma.

Jaypirca therapy improved progression-free survival versus bendamustine plus Rituxan a phase 3 trial for untreated CLL/SLL.

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Lore Gruenbaum, chief scientific officer of Blood Cancer United, sat down for an interview with CURE to discuss the themes shaping blood cancer care today.

Dr. Josh Brody discussed key clinical trial findings for patients with diffuse large B-cell lymphoma.

Xervyteg improved responses and was safe in steroid- and Jakafi-resistant acute graft-versus-host disease affecting the GI tract in a phase 3 trial.

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

The phase 3 EPCORE FL-1 trial showed that adding Epkinly to Rituxan and Revlimid delivered superior PFS and response rates.

A new combination of Blincyto and Iclusig provided improved results and stronger responses for patients with Philadelphia chromosome-positive ALL compared with traditional chemotherapy.

Among fit patients with acute myeloid leukemia, azacitidine plus Venclexta was shown to be superior to intensive chemotherapy.

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), Epkinly plus R-mini-CHOP appeared to be well tolerated and elicited responses.

Transitioning treatment with Niktimvo to a dose of 0.6 mg/kg every four weeks appeared feasible for chronic graft-versus-host disease.

Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.